Anzeige
Mehr »
Login
Mittwoch, 01.04.2020 Börsentäglich über 12.000 News von 624 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0DNPW ISIN: AU000000MSB8 Ticker-Symbol: LWB 
Tradegate
01.04.20
09:31 Uhr
0,845 Euro
+0,060
+7,64 %
Branche
Biotechnologie
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
MESOBLAST LIMITED Chart 1 Jahr
5-Tage-Chart
MESOBLAST LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
0,825
0,850
16:34
0,820
0,845
16:35

Aktuelle News zur MESOBLAST Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MESOBLAST Aktie jetzt für 4€ handeln
12:46FDA accepts Mesoblast's application for graft versus host disease treatment-
12:34FDA accepts Mesoblast's application for cell therapy for graft versus host disease-
12:10Mesoblast Limited: FDA ACCEPTS MESOBLAST'S BIOLOGICS LICENCE APPLICATION FOR RYONCIL AND AGREES TO PRIORITY REVIEW-
03:04Why Mesoblast, Redbubble, Santos, & Scentre shares are surging higher1
01:47BRIEF-Mesoblast Says U.S. FDA Accepted For Priority Review Co's Biologics License Application Filing For Ryonciltm (Remestemcel-L)1
01:34Mesoblast share price jumps 12% on FDA update1
DiMESOBLAST LIMITED: FDA Accepts BLA for RYONCIL and Agrees to Priority Review-
MoMesoblast up 8% on positive Revascor data3
MoMesoblast up 8% on positive Revascore data1
MoMesoblast Limited: CLINICAL OUTCOMES OF MESOBLAST'S CELL THERAPY IN END-STAGE ISCHEMIC HEART FAILURE PRESENTED AT AMERICAN COLLEGE OF CARDIOLOGY VIRTUAL ...4
MoMESOBLAST LIMITED: Ischemic End Stage HF Outcomes at Virtual ACC Annual Meeting1
20.03.MESOBLAST LIMITED: Change of Director's Interest Notice13
17.03.MESOBLAST LIMITED: Appendix 2A14
16.03.Mesoblast - An important next several months298It is going to be a busy next several months for Mesoblast. The company recently completed filing the biologics license application (BLA) for Ryoncil (remestemcel-L) with the FDA for approval for the...
► Artikel lesen
10.03.The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index18
10.03.Stock Alert: Mesoblast To Take A Shot At Coronavirus; Stock Up 28%15
10.03.Mesoblast up 12% premarket on entry into COVID-199
10.03.Mesoblast Limited: Mesoblast To Evaluate Anti-Inflammatory Cell Therapy Remestemcel-L For Treatment Of COVID-19 Lung Disease2
10.03.Mesoblast to trial anti-inflammatory infusions in COVID-19 patients with respiratory distress6
10.03.BRIEF-Mesoblast To Evaluate Anti-Inflammatory Cell Therapy For COVID-193
Seite:  Weiter >>
91 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2